Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.

Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.

Item
http://www.wikidata.org/entity/Q41636433
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsTuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.Safety of mTOR inhibitors in adult solid organ transplantation.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus
P2860

Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.

Item
http://www.wikidata.org/entity/Q41636433
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Everolimus-based immunosuppres ...... ents: impact on CMV infection.
@en
type
label
Everolimus-based immunosuppres ...... ents: impact on CMV infection.
@en
prefLabel
Everolimus-based immunosuppres ...... ents: impact on CMV infection.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Everolimus-based immunosuppres ...... ents: impact on CMV infection.
@en
P2093
P304
P31
P356
10.1016/J.ANTIVIRAL.2014.10.016
P478
P50
P577
P5875
P698
P921